-

Dr. Ferrer BioPharma Awarded Winner at CPHI Pharmapack 2024 for Groundbreaking GentleMist Technology

PARIS--(BUSINESS WIRE)--Marking a milestone in pharmaceutical innovation and excellence, Dr. Ferrer BioPharma has been honored with a prestigious award at the renowned CPHI Pharmapack 2024, which took place at the Paris Expo, Porte de Versailles. The company’s groundbreaking GentleMist Technology received the "Patient-Centric Design" award, highlighting its revolutionary approach in intranasal drug delivery.

The GentleMist Technology represents a paradigm shift in the administration of medications as a cutting-edge intranasal drug delivery device that revolutionizes how medications are administered. Moving beyond the limitations of traditional nozzles, which causes discomfort, GentleMist Technology utilizes advanced fluid dynamics principles to create a gentler and more effective nasal spray. This innovative approach not only reduces discomfort but maximizes drug target delivery and optimizes droplet size distribution for improved absorption. Developed through a collaborative effort with leading fluid dynamics and clinical scientists from South Dakota State University, Bona Pharma, and the Cleveland Clinic, GentleMist Technology has shown superior performance, significantly enhancing patient comfort and therapeutic outcomes. With over 26 million units sold in the USA, Europe and the Caribbean, GentleMist Technology has achieved widespread acceptance and garnered positive patient experiences.

CPHI Pharmapack Awards serves as a prestigious platform for showcasing global innovation and highlights the industry’s commitment to progress and patient-centered solutions. Dr. Ferrer BioPharma's success at this prestigious event underscores its dedication to improving patient care through innovative pharmaceutical technologies.

Dr. Ferrer BioPharma holds multiple patents for medications and devices, distinguishing themselves by utilizing their proprietary GentleMist Technology in all their nasal and throat sprays. This unique feature provides a distinct advantage over competitors.

Nestled within the flourishing life sciences sector of South Florida, Dr. Ferrer BioPharma actively collaborates with local government initiatives, including those facilitated by the Broward County Office of Economic and Small Business Development.

Contacts

Daniel Fernández
Marketing Director
+1-954-225-7694
marketing@pulmonary-institute.com

Dr. Ferrer BioPharma



Contacts

Daniel Fernández
Marketing Director
+1-954-225-7694
marketing@pulmonary-institute.com

Social Media Profiles
More News From Dr. Ferrer BioPharma

Moxie Health Group Hosts First-Ever Moxiethon Hackathon in Honduras, Uniting Students to Innovate the Future of Healthcare

SAN PEDRO SULA, Honduras--(BUSINESS WIRE)--Moxie Health hosts first MoxieThon Hackathon in Honduras, uniting students to develop AI-driven healthcare solutions through Moxie-Link....

ClorNovir by Dr. Ferrer BioPharma Named Finalist at CPHI Pharma Awards 2024 for Breakthrough COVID-19 and Post-COVID Care

MILAN--(BUSINESS WIRE)--ClorNovir by Dr. Ferrer BioPharma is a CPHI Pharma Awards 2024 finalist for its innovative COVID-19 and post-COVID care nasal spray solution....

Dr. Ferrer BioPharma Named Finalist for CPhI Pharma Awards 2023

HALLANDALE BEACH, Fla.--(BUSINESS WIRE)--Dr. Ferrer BioPharma (DFB) is honored to be a finalist for the prestigious CPhI Pharma Worldwide Awards 2023, an internationally renowned award platform organized by CPhI, the world's leading pharmaceutical networking event. DFB has achieved consecutive recognition as a finalist for three years running: in 2021, they were acknowledged for their Innovation in Response to COVID-19; in 2021 and 2022, they were finalists in the Finished Formulation category;...
Back to Newsroom